32,297 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by Troluce Capital Advisors LLC

Troluce Capital Advisors LLC bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 32,297 shares of the company's stock, valued at approximately $1,729,000. Janux Therapeutics comprises 0.1% of Troluce Capital Advisors LLC's investment portfolio, making the stock its 20th largest position. Troluce Capital Advisors LLC owned 0.06% of Janux Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC boosted its stake in Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Franklin Resources Inc. boosted its stake in Janux Therapeutics by 64.5% during the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock worth $937,000 after purchasing an additional 7,442 shares during the period. Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics in the 4th quarter worth $139,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after acquiring an additional 1,095 shares during the period. Finally, Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics in the 4th quarter worth $230,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Down 2.5%

Shares of JANX traded down $0.63 during mid-day trading on Wednesday, hitting $24.77. The company had a trading volume of 748,634 shares, compared to its average volume of 868,767. The business's 50-day simple moving average is $28.38 and its 200-day simple moving average is $40.22. Janux Therapeutics, Inc. has a 1-year low of $22.48 and a 1-year high of $71.71. The stock has a market cap of $1.47 billion, a PE ratio of -21.17 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on JANX shares. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Scotiabank dropped their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. Finally, Wedbush restated an "outperform" rating and set a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and an average price target of $95.25.

Insider Buying and Selling

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at $2,630,912.17. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock in a transaction dated Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the transaction, the director now owns 10,141,287 shares of the company's stock, valued at approximately $314,582,722.74. This represents a 1.10% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 10,001 shares of company stock valued at $313,964. Insiders own 29.40% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.